Active 0 6 0 6 O
central 7 14 7 14 O
nervous 15 22 15 22 O
system 23 29 23 29 O
( 30 31 30 31 O
CNS 31 34 31 34 O
) 34 35 34 35 O
or 36 38 36 38 O
extramedullary 39 53 39 53 B-cancer
disease 54 61 54 61 I-cancer

Bilirubin 0 9 62 71 B-clinical_variable
less 10 14 72 76 O
than 15 19 77 81 O
or 20 22 82 84 O
equal 23 28 85 90 O
to 29 31 91 93 O
3.0 32 35 94 97 B-upper_bound
mg 36 38 98 100 I-upper_bound
/ 38 39 100 101 I-upper_bound
dL 39 41 101 103 I-upper_bound

Creatinine 0 10 104 114 B-clinical_variable
clearance 11 20 115 124 I-clinical_variable
> 21 22 125 126 O
= 22 23 126 127 O
30 24 26 128 130 B-lower_bound
ml 27 29 131 133 I-lower_bound
/ 29 30 133 134 I-lower_bound
minute 30 36 134 140 I-lower_bound

Known 0 5 141 146 O
to 6 8 147 149 O
be 9 11 150 152 O
human 12 17 153 158 B-chronic_disease
immunodeficiency 18 34 159 175 I-chronic_disease
virus 35 40 176 181 I-chronic_disease
positive 41 49 182 190 I-chronic_disease
( 50 51 191 192 I-chronic_disease
HIV+ 51 55 192 196 I-chronic_disease
) 55 56 196 197 I-chronic_disease

Monoclonal 0 10 198 208 B-treatment
antibodies 11 21 209 219 I-treatment
therapy 22 29 220 227 I-treatment
within 30 36 228 234 O
2 37 38 235 236 B-upper_bound
weeks 39 44 237 242 I-upper_bound
before 45 51 243 249 I-upper_bound
study 52 57 250 255 O
entry 58 63 256 261 O

No 0 2 262 264 O
active 3 9 265 271 O
or 10 12 272 274 O
co 13 15 275 277 O
- 15 16 277 278 O
existing 16 24 278 286 O
malignancy 25 35 287 297 B-cancer

Patients 0 8 298 306 O
with 9 13 307 311 O
B 14 15 312 313 B-cancer
- 15 16 313 314 I-cancer
lineage 16 23 314 321 I-cancer
ALL 24 27 322 325 I-cancer
in 28 30 326 328 O
hematologic 31 42 329 340 O
complete 43 51 341 349 O
remission 52 61 350 359 O
( 62 63 360 361 O
CR 63 65 361 363 O
) 65 66 363 364 O
with 67 71 365 369 O
molecular 72 81 370 379 O
failure 82 89 380 387 O
( 90 91 388 389 O
i.e. 91 95 389 393 O
, 95 96 393 394 O
had 97 100 395 398 O
never 101 106 399 404 O
achieved 107 115 405 413 O
an 116 118 414 416 O
MRD 119 122 417 420 B-cancer
- 122 123 420 421 O
negativity 123 133 421 431 O
status 134 140 432 438 O
before 141 147 439 445 O
blinatumomab 148 160 446 458 B-treatment
) 160 161 458 459 O
or 162 164 460 462 O
had 165 168 463 466 O
a 169 170 467 468 O
molecular 171 180 469 478 O
relapse 181 188 479 486 O
( 189 190 487 488 O
i.e. 190 194 488 492 O
, 194 195 492 493 O
became 196 202 494 500 O
MRD 203 206 501 504 O
positive 207 215 505 513 O
after 216 221 514 519 O
having 222 228 520 526 O
been 229 233 527 531 O
MRD 234 237 532 535 O
negative 238 246 536 544 O
) 246 247 544 545 O
starting 248 256 546 554 O
at 257 259 555 557 O
any 260 263 558 561 O
time 264 268 562 566 O
point 269 274 567 572 O
after 275 280 573 578 O
3 281 282 579 580 B-upper_bound
months 283 289 581 587 I-upper_bound
of 290 292 588 590 O
frontline 293 302 591 600 B-treatment
therapy 303 310 601 608 I-treatment
; 310 311 608 609 O
molecular 312 321 610 619 B-chronic_disease
disease 322 329 620 627 I-chronic_disease
or 330 332 628 630 I-chronic_disease
minimal 333 340 631 638 I-chronic_disease
residual 341 349 639 647 I-chronic_disease
disease 350 357 648 655 I-chronic_disease
is 358 360 656 658 O
defined 361 368 659 666 O
by 369 371 667 669 O
a 372 373 670 671 O
value 374 379 672 677 O
of 380 382 678 680 O
at 383 385 681 683 O
least 386 391 684 689 O
of 392 394 690 692 O
1 395 396 693 694 B-lower_bound
x 397 398 695 696 I-lower_bound
10 399 401 697 699 I-lower_bound
- 401 402 699 700 I-lower_bound
4 402 403 700 701 I-lower_bound
( 404 405 702 703 I-lower_bound
0.01 405 409 703 707 I-lower_bound
% 409 410 707 708 I-lower_bound
) 410 411 708 709 I-lower_bound
by 412 414 710 712 O
multicolor 415 425 713 723 O
flow 426 430 724 728 O
cytometry 431 440 729 738 O
and/or 441 447 739 745 O
by 448 450 746 748 O
next 451 455 749 753 O
generation 456 466 754 764 O
sequencing 467 477 765 775 O
( 478 479 776 777 O
NGS 479 482 777 780 O
) 482 483 780 781 O

Patients 0 8 782 790 O
with 9 13 791 795 O
B 14 15 796 797 B-cancer
- 15 16 797 798 I-cancer
lineage 16 23 798 805 I-cancer
acute 24 29 806 811 I-cancer
lymphocytic 30 41 812 823 I-cancer
leukemia 42 50 824 832 I-cancer
( 51 52 833 834 I-cancer
ALL 52 55 834 837 I-cancer
) 55 56 837 838 I-cancer
in 57 59 839 841 O
hematologic 60 71 842 853 B-treatment
complete 72 80 854 862 I-treatment
remission 81 90 863 872 I-treatment
( 91 92 873 874 I-treatment
CR 92 94 874 876 I-treatment
) 94 95 876 877 I-treatment
with 96 100 878 882 O
molecular 101 110 883 892 B-chronic_disease
failure 111 118 893 900 I-chronic_disease
( 119 120 901 902 O
i.e. 120 124 902 906 O
, 124 125 906 907 O
had 126 129 908 911 O
never 130 135 912 917 O
achieved 136 144 918 926 O
an 145 147 927 929 O
MRD 148 151 930 933 O
- 151 152 933 934 O
negativity 152 162 934 944 O
status 163 169 945 951 O
before 170 176 952 958 O
blinatumomab 177 189 959 971 B-treatment
) 189 190 971 972 O
or 191 193 973 975 O
had 194 197 976 979 O
a 198 199 980 981 O
molecular 200 209 982 991 O
relapse 210 217 992 999 O
( 218 219 1000 1001 O
i.e. 219 223 1001 1005 O
, 223 224 1005 1006 O
became 225 231 1007 1013 O
MRD 232 235 1014 1017 O
positive 236 244 1018 1026 O
after 245 250 1027 1032 O
having 251 257 1033 1039 O
been 258 262 1040 1044 O
MRD 263 266 1045 1048 O
negative 267 275 1049 1057 O
) 275 276 1057 1058 O
starting 277 285 1059 1067 O
at 286 288 1068 1070 O
any 289 292 1071 1074 O
time 293 297 1075 1079 O
point 298 303 1080 1085 O
after 304 309 1086 1091 B-upper_bound
3 310 311 1092 1093 I-upper_bound
months 312 318 1094 1100 I-upper_bound
of 319 321 1101 1103 O
frontline 322 331 1104 1113 B-treatment
therapy 332 339 1114 1121 I-treatment
; 339 340 1121 1122 O
molecular 341 350 1123 1132 B-chronic_disease
disease 351 358 1133 1140 I-chronic_disease
or 359 361 1141 1143 O
minimal 362 369 1144 1151 B-cancer
residual 370 378 1152 1160 I-cancer
disease 379 386 1161 1168 I-cancer
is 387 389 1169 1171 O
defined 390 397 1172 1179 O
by 398 400 1180 1182 O
a 401 402 1183 1184 O
value 403 408 1185 1190 O
of 409 411 1191 1193 O
at 412 414 1194 1196 O
least 415 420 1197 1202 O
of 421 423 1203 1205 O
1 424 425 1206 1207 B-lower_bound
x 426 427 1208 1209 I-lower_bound
10 428 430 1210 1212 I-lower_bound
^ 430 431 1212 1213 I-lower_bound
-4 431 433 1213 1215 I-lower_bound
( 434 435 1216 1217 O
0.01 435 439 1217 1221 O
% 439 440 1221 1222 O
) 440 441 1222 1223 O
by 442 444 1224 1226 O
multicolor 445 455 1227 1237 O
flow 456 460 1238 1242 O
cytometry 461 470 1243 1252 O
and/or 471 477 1253 1259 O
by 478 480 1260 1262 O
next 481 485 1263 1267 O
generation 486 496 1268 1278 O
sequencing 497 507 1279 1289 O
( 508 509 1290 1291 O
NGS 509 512 1291 1294 O
) 512 513 1294 1295 O

Patients 0 8 1296 1304 O
with 9 13 1305 1309 O
Philadelphia 14 26 1310 1322 B-cancer
chromosome 27 37 1323 1333 I-cancer
positive 38 46 1334 1342 I-cancer
( 47 48 1343 1344 I-cancer
Ph+ 48 51 1344 1347 I-cancer
) 51 52 1347 1348 I-cancer
ALL 53 56 1349 1352 I-cancer
can 57 60 1353 1356 O
be 61 63 1357 1359 O
enrolled 64 72 1360 1368 O
in 73 75 1369 1371 O
CR1 76 79 1372 1375 O
or 80 82 1376 1378 O
CR2 83 86 1379 1382 O
and 87 90 1383 1386 O
beyond 91 97 1387 1393 O
; 97 98 1393 1394 O
a 99 100 1395 1396 O
tyrosine 101 109 1397 1405 B-treatment
kinase 110 116 1406 1412 I-treatment
inhibitor 117 126 1413 1422 I-treatment
( 127 128 1423 1424 I-treatment
TKI 128 131 1424 1427 I-treatment
) 131 132 1427 1428 I-treatment
will 133 137 1429 1433 O
be 138 140 1434 1436 O
added 141 146 1437 1442 O
at 147 149 1443 1445 O
the 150 153 1446 1449 O
discretion 154 164 1450 1460 O
of 165 167 1461 1463 O
the 168 171 1464 1467 O
treating 172 180 1468 1476 O
physician 181 190 1477 1486 O
; 190 191 1486 1487 O
MRD 192 195 1488 1491 B-clinical_variable
for 196 199 1492 1495 O
these 200 205 1496 1501 O
patients 206 214 1502 1510 O
will 215 219 1511 1515 O
be 220 222 1516 1518 O
defined 223 230 1519 1526 O
by 231 233 1527 1529 O
PCR 234 237 1530 1533 O
of 238 240 1534 1536 O
0.1 241 244 1537 1540 B-lower_bound
% 244 245 1540 1541 I-lower_bound
and 246 249 1542 1545 O
above 250 255 1546 1551 O
( 256 257 1552 1553 O
International 257 270 1553 1566 O
Scale 271 276 1567 1572 O
) 276 277 1572 1573 O

Performance 0 11 1574 1585 B-clinical_variable
status 12 18 1586 1592 I-clinical_variable
of 19 21 1593 1595 O
0 22 23 1596 1597 B-lower_bound
, 23 24 1597 1598 O
1 25 26 1599 1600 O
, 26 27 1600 1601 O
or 28 30 1602 1604 O
2 31 32 1605 1606 B-upper_bound

Pregnant 0 8 1607 1615 B-pregnancy

Radiotherapy 0 12 1616 1628 B-treatment
and 13 16 1629 1632 I-treatment
cancer 17 23 1633 1639 I-treatment
chemotherapy 24 36 1640 1652 I-treatment
( 37 38 1653 1654 O
except 38 44 1654 1660 O
for 45 48 1661 1664 O
intrathecal 49 60 1665 1676 O
prophylaxis 61 72 1677 1688 O
and/or 73 79 1689 1695 O
low 80 83 1696 1699 O
- 83 84 1699 1700 O
dose 84 88 1700 1704 O
maintenance 89 100 1705 1716 B-treatment
therapy 101 108 1717 1724 I-treatment
such 109 113 1725 1729 I-treatment
as 114 116 1730 1732 I-treatment
vinca 117 122 1733 1738 I-treatment
alkaloids 123 132 1739 1748 I-treatment
, 132 133 1748 1749 O
mercaptopurine 134 148 1750 1764 B-treatment
, 148 149 1764 1765 O
methotrexate 150 162 1766 1778 B-treatment
, 162 163 1778 1779 O
steroids 164 172 1780 1788 B-treatment
) 172 173 1788 1789 O
or 174 176 1790 1792 O
any 177 180 1793 1796 O
investigational 181 196 1797 1812 B-treatment
drug 197 201 1813 1817 I-treatment
within 202 208 1818 1824 O
2 209 210 1825 1826 B-upper_bound
weeks 211 216 1827 1832 I-upper_bound
before 217 223 1833 1839 O
study 224 229 1840 1845 O
entry 230 235 1846 1851 O

life 0 4 1852 1856 B-clinical_variable
expectancy 5 15 1857 1867 I-clinical_variable
less 16 20 1868 1872 O
than 21 25 1873 1877 O
12 26 28 1878 1880 B-upper_bound
months 29 35 1881 1887 I-upper_bound

nursing 0 7 1888 1895 O
women 8 13 1896 1901 B-gender

